secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2026-03-03T23:59:59+00:00
Accession:  0001104659-26-022830
Event type: m_and_a
Sentiment:  positive
Materiality: 0.65
Item codes: 3.02, 8.01, 3.03, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode acquires exclusive license to oncolytic immunotherapy platform in all-stock deal
--------------------------------------------------------------------------------

- Issued 1,136,364 shares of Series C non-voting convertible preferred to Unleash; convertible to common after stockholder approval.
- Preferred stock represents 6.8% of TransCode's fully diluted common stock.
- Lead candidate UIO-524 targets muscle-invasive bladder cancer (MIBC), a high-unmet-need indication.
- License is exclusive, worldwide, fully paid-up, royalty-free; no future cash payments.
- Tungsten Advisors received 77,841 Series C shares as financial advisor compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465926022830/0001104659-26-022830-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465926022830/tm267831d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-022830

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer